• Nano24 announces that Phase 2b trial of its EXO-CD24 inhaled exosome in ARDS met its primary endpoint

  Israeli biotech Nano24 announced that a Phase 2b trial of nebulized EXO-CD24 exosomes in patients with acute respiratory distress syndrome met its primary endpoint, with 85% of patients who received EXO-CD24 having an SpO2/FiO2 >315… [Read more . . .]

• FDA clears United Therapeutics IND for Phase 2 SUMMIT trial of treprostinil SMI in patients with PH-COPD

  According to United Therapeutics, the FDA has cleared the company’s IND for the 16-week Phase 2 SUMMIT trial of treprostinil SMI in patients with pulmonary hypertension associated with COPD, which is expected to enroll approximately… [Read more . . .]

• Aptar Pharma’s LuerVax intranasal vaccine delivery device gets CE mark

  Aptar Pharma’s LuerVax single-use nasal vaccine delivery device is now CE marked, the company announced. An optional accessory that allows for division of the vaccine so that half of the dose can be sprayed into… [Read more . . .]

• Liquidia settles with United Therapeutics, Yutrepia treprostinil DPI will continue to be available for PAH

  According to Liquidia, the company has reached a settlement with United Therapeutics to end all litigation related to patent infringement by Liquidia’s Yutrepia treprostinil DPI. A United States District Court judge recently ruled that Yutrepia… [Read more . . .]

• Aptar announces the addition of OINDP manufacturing capacity at its Mumbai, India facility

  Aptar Pharma has announced the addition of molding capabilities to its OINDP manufacturing facility in Mumbai, India, which was opened in 2023. Products produced at the plant include MDI valves, breath-actuated inhalers, and nasal delivery devices.… [Read more . . .]

• Bespak to offer nasal dry powder delivery device under MOU with SNBL

• Lupin launches Formoflo-G glypocyrronium / formoterol / fluticasone MDI for the treatment of COPD in India

• Liquidia to submit sNDA to remove PH-ILD indication from Yutrepia treprostinil DPI after court finds that it infringes claims in United Therapeutics patent covering Tyvaso

• Bespak launches its new NasaDose Ultra Soft Unit Dose Spray nasal delivery device

• Nasus Pharma initiates Phase 1 trial of NS003 intranasal dry powder ondansetron

More news . . .